Clinical trials: Cytomegalovirus Retinitis
HIV Infections, Cytomegalovirus Retinitis
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial treatment of patients with cytomegalovirus (CMV) retinitis.
- Trial name
- FGCRT (NCT00000136)
- Testing
- Foscarnet, Ganciclovir
- Volunteers
- 234 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections, Acquired Immunodeficiency Syndrome
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed.
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- CRRT (NCT00000134)
- Testing
- Ganciclovir, Foscarnet
- Volunteers
- 279 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections, Acquired Immunodeficiency Syndrome
Longitudinal Study of Ocular Complications of AIDS (LSOCA)
To monitor trends over time, in the incidence of CMV retinitis and other ocular complications of AIDS To determine the effect of highly active anti-retroviral therapy (HAART)-induced immune status on the risk of developing CMV…
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- LSOCA (NCT00000168)
- Where
- 19 sites in United States
- Volunteers
- 2,392 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cytomegalovirus Retinitis, Acute Renal Failure
Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
Cidofovir is an acyclic nucleotide analog with broad-spectrum antiviral activity against herpesviruses. Its potency in inhibiting HCMV has been shown in conventional in vitro studies.
- Trial name
- NCT01866397
- Testing
- Cidofovir pharmacokinetics
- Where
- Austria
- Volunteers
- 1 people
- Sponsor
- Medical University of Vienna
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS
To find oral doses of FIAC (a pyrimidine nucleoside analog) that are effective in treating cytomegalovirus (CMV) viremia in HIV-infected immunocompromised patients; to determine tolerance and safety of FIAC in this patient…
- Trial name
- NCT00000981
- Testing
- Fiacitabine
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol
To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC) for treatment of small peripheral cytomegalovirus (CMV) retinitis lesions.
- Trial name
- NCT00000799
- Testing
- Cidofovir, Probenecid
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)
To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus active primary treatment in AIDS patients with newly…
- Trial name
- NCT00000836
- Testing
- Sevirumab
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
To evaluate the relative effectiveness and safety of foscarnet versus ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in people with AIDS; to evaluate the relative effect on survival of the use of these two…
- Trial name
- NCT00000665
- Testing
- Foscarnet sodium, Ganciclovir
- Where
- 9 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
To provide information about the usefulness and safety of giving injections of ganciclovir (DHPG) for treating peripheral cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00000688
- Testing
- Ganciclovir
- Where
- 22 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
CMV Retinitis Retreatment Trial
To assess the safety and efficacy of three therapeutic regimens (foscarnet, ganciclovir, or the combination) for recurrent or persistent AIDS-related cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00000766
- Testing
- Foscarnet sodium, Ganciclovir
- Where
- 9 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
To compare cidofovir with a commonly used treatment regimen, ganciclovir given by mouth (oral) and through an eye device (intraocular) , in order to determine the safety and effectiveness of cidofovir in preventing vision loss in…
- Trial name
- NCT00000894
- Testing
- Cidofovir, Probenecid, Ganciclovir
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Acquired Immunodeficiency Syndrome
Ganciclovir Implant Study for Cytomegalovirus Retinitis
To determine the therapeutic efficacy of a sustained-release intraocular drug delivery system for ganciclovir therapy of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- NCT00000118
- Testing
- Sustained-Release Intraocular Drug Delivery System
- Sponsor
- National Eye Institute (NEI)
Cytomegalovirus Retinitis, HIV Infections
A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis
To determine the safety and effectiveness of intravenous ganciclovir (also known as DHPG) in the treatment of sight-threatening cytomegalovirus (CMV) retinitis in patients with AIDS.
- Trial name
- NCT00000698
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, Cytomegalovirus Retinitis
A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection
The purpose of this study is to understand how changes in the immune system of HIV-infected patients affect their risk for 3 serious infections: Pneumocystis carinii pneumonia (PCP), cytomegalovirus (CMV) retinitis, or CMV organ…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, Pneumonia, Pneumocystis Carinii, HIV Infections
- Trial name
- NCT00005572
- Where
- 16 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy
The purpose of this study is to see if it is safe to stop maintenance therapy in HIV-positive patients with treated and healed CMV retinitis (eye disease) who have responded well to anti-HIV (antiretroviral) therapy.
- Trial name
- NCT00000905
- Where
- 25 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Immune Activity Against CVM Retinitis
This study will investigate whether medication for cytomegalovirus (CMV) retinitis-a viral infection of the eye-can safely be stopped in HIV-infected patients whose immune function has improved from anti-HIV therapy.
- Conditions
- Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis, HIV Infection
- Trial name
- NCT00001611
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
Efficacy of Elevated CD4 Counts on CMV Retinitis
Some patients with HIV/AIDS suffer from a dangerous viral infection of the retina (and other organs) called cytomegalovirus infection (CMV). The medications currently used to treat CMV all have serious side effects.
- Trial name
- NCT00091884
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Cytomegalovirus Retinitis, HIV Infections
A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS
To evaluate whether immune globulin and ganciclovir (DHPG) results in faster initial response as compared to DHPG alone. To evaluate whether immune globulin and DHPG gives longer duration of remission than DHPG alone (i.e.
- Trial name
- NCT00001999
- Testing
- Globulin, Immune, Ganciclovir
- Where
- United States
- Sponsor
- American National Red Cross
Cytomegalovirus Retinitis, HIV Infections
An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir IV in immunocompromised children receiving…
- Trial name
- NCT00002015
- Testing
- Ganciclovir
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Roche Global Development
Cytomegalovirus Retinitis, HIV Infections
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
To determine the safety and tolerance of 3 dosage levels of human anti-cytomegalovirus (CMV) monoclonal antibody (SDZ MSL-109) when administered once every 2 weeks for a total of 8 doses during the maintenance phase of…
- Trial name
- NCT00002016
- Testing
- Sevirumab
- Where
- 2 sites in United States
- Sponsor
- Sandoz